The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://bookmarkshq.com/story23495428/tirzepatide-and-nad-a-integrated-strategy-to-physiological-health